Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer

NCT04033432 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT04033432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04033432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Unknown status
Start date
September 20, 2019
Completion date
June 30, 2022
Enrollment
14 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

castration levels of testosterone, castration-resistant prostate carcinoma, castration-resistant prostate carcinoma refractory to second-generation androgen receptor axis-targeted agents, metastatic prostate adenocarcinoma, progressive disease, prostate carcinoma metastatic in the bone, prostate carcinoma metastatic in the soft tissue, psa progression, stage ivb prostate cancer ajcc v8, testosterone less than 50 ng/dl